Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 293-310 , June 2006

Role of lifestyle modification in the management of polycystic ovary syndrome

  • Kathleen M. Hoeger, MD (Associate Professor of Obstetrics & Gynecology)

      Affiliations

    • Corresponding Author InformationTel.: +1 585 275 7891; fax: +1 585 756 5717.

References 

  1. National Vital Statistics Report: Center for disease control and prevention national center for health statistics; Report No.; 2002; 50(2).
  2. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obesity Reviews. 2005;6(1):5–7
  3. Freedman DS, Khan LK, Serdula MK, et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. The Journal of the American Medical Association. 2002;288(14):1758–1761
  4. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. The Journal of the American Medical Association. 2002;288(14):1723–1727
  5. Flegal KM, Ogden CL, Carroll MD. Prevalence and trends in overweight in Mexican–American adults and children. Nutrition Reviews. 2004;62(7 Pt 2):S144–S148
  6. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999–2000. The Journal of the American Medical Association. 2002;288(14):1728–1732
  7. Popkin BM, Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. International Journal of Obesity and Related Metabolic Disorders. 2004;28(supplement 3):S2–S9
  8. Stein IF, Levinthal ML. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology. 1935;(29):181–191
  9. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2745–2749
  10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The Journal of Clinical Endocrinology and Metabolism. 1999;84(1):165–169
  11. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of Clinical Endocrinology and Metabolism. 2000;85(7):2434–2438
  12. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. The Journal of Clinical Endocrinology and Metabolism. 1999;84(11):4006–4011
  13. Carmina E. Genetic and environmental aspect of polycystic ovary syndrome. Journal of Endocrinological Investigation. 2003;26(11):1151–1159
  14. Chang JNR, Judd HL, Kaplan SA. Insulin resistance in non-obese patients with polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabolism. 1983;57:356–359
  15. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–1174
  16. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774–800
  17. Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutrition Reviews. 2003;61(12):397–412
  18. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48(2):167–172
  19. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 1988;66(1):131–139
  20. Cibula D. Is insulin resistance an essential component of PCOS? The influence of confounding factors. Human Reproduction (Oxford, England). 2004;19(4):757–759
  21. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–146
  22. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction (Oxford, England). 2001;16(9):1995–1998
  23. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. The Journal of Clinical Endocrinology and Metabolism. 2005;90(6):3236–3242
  24. Qiao Q, Tuomilehto J. Diagnostic criteria of glucose intolerance and mortality. Minerva Medica. 2001;92(2):113–119
  25. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group . Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ (Clinical research ed. ). 1998;317(7155):371–375
  26. DECODE Study Group, the European Diabetes Epidemiology Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine. 2001;161(3):397–405
  27. Van Pelt RE, Jankowski CM, Gozansky WS, et al. Lower-body adiposity and metabolic protection in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. 2005;90(8):4573–4578
  28. Frayn KN. Visceral fat and insulin resistance—causative or correlative?. The British Journal of Nutrition. 2000;83(supplement 1):S71–S77
  29. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;83(supplement 1):S143–S151
  30. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiologica Scandinavica. 2005;183(1):13–30
  31. Rebuffe-Scrive M, Cullberg G, Lundberg PA, et al. Anthropometric variables and metabolism in polycystic ovarian disease. Hormone and Metabolic Research. 1989;21(7):391–397
  32. Douchi T, Ijuin H, Nakamura S, et al. Body fat distribution in women with polycystic ovary syndrome. Obstetrics and Gynecology. 1995;86(4 Pt 1):516–519
  33. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertility and Sterility. 2003;79(6):1358–1364
  34. Norman RJ, Masters SC, Hague W, et al. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertility and Sterility. 1995;63(2):329–335
  35. Puder JJ, Varga S, Kraenzlin M, et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. The Journal of Clinical Endocrinology and Metabolism. 2005;90(11):6014–6021
  36. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735–2752
  37. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–1250
  38. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385–390
  39. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome (PCOS). The Journal of Clinical Endocrinology. 2005;
  40. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics and Gynecology. 2005;106(1):131–137
  41. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Obstetrical & Gynecological Survey. 2005;60(9):589–591
  42. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. European Journal of Endocrinology. 2004;150(2):161–171
  43. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clinical Endocrinology. 1990;32(2):213–220
  44. Franks S, Kiddy D, Sharp P, et al. Obesity and polycystic ovary syndrome. Annals of the New York Academy of Sciences. 1991;626:201–206
  45. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clinical Endocrinology. 1994;41(4):473–481
  46. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. European Journal of Endocrinology. 2004;150(4):525–532
  47. Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. The Journal of Clinical Endocrinology and Metabolism. 1996;81(8):2854–2864
  48. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. The Journal of Clinical Endocrinology and Metabolism. 1997;82(11):3728–3733
  49. Shepard MKJB, Leija CG. Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertility and Sterility. 1979;32(6):641–645
  50. Friedman CI, Kim MH. Obesity and its effect on reproductive function. Clinical Obstetrics and Gynecology. 1985;28(3):645–663
  51. Dickey RP, Taylor SN, Curole DN, et al. Relationship of clomiphene dose and patient weight to successful treatment. Human Reproduction (Oxford, England). 1997;12(3):449–453
  52. Imani BME, Te Velde ER, Habbeman JDF, Fauser BCJM. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2361–2365
  53. Imani B, Eijkemans MJ, te Velde ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertility and Sterility. 2002;77(1):91–97
  54. McClure N, McQuinn B, McDonald J, et al. Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome?. Fertility and Sterility. 1992;58(3):622–624
  55. Hamilton-Fairley D, Kiddy D, Watson H, et al. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. British Journal of Obstetrics and Gynaecology. 1992;99(2):128–131
  56. White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. The Journal of Clinical Endocrinology and Metabolism. 1996;81(11):3821–3824
  57. Imani B, Eijkemans MJ, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertility and Sterility. 2002;77(1):83–90
  58. Fedorcsak P, Dale PO, Storeng R, et al. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Human Reproduction (Oxford, England). 2001;16(6):1086–1091
  59. Fedorcsak P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Human Reproduction (Oxford, England). 2004;19(11):2523–2528
  60. Spandorfer SD, Kump L, Goldschlag D, et al. Obesity and in vitro fertilization: negative influences on outcome. The Journal of Reproductive Medicine. 2004;49(12):973–977
  61. Lashen H, Ledger W, Bernal AL, Barlow D. Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilization. Human Reproduction (Oxford, England). 1999;14(3):712–715
  62. Ferlitsch K, Sator MO, Gruber DM, et al. Body mass index, follicle-stimulating hormone and their predictive value in in vitro fertilization. Journal of Assisted Reproduction and Genetics. 2004;21(12):431–436
  63. van Swieten EC, van der Leeuw-Harmsen L, Badings EA, van der Linden PJ. Obesity and clomiphene challenge test as predictors of outcome of in vitro fertilization and intracytoplasmic sperm injection. Gynecologic and Obstetric Investigation. 2005;59(4):220–224
  64. Lintsen AM, Pasker-de Jong PC, de Boer EJ, et al. Effects of subfertility cause, smoking and body weight on the success rate of IVF. Human Reproduction (Oxford, England). 2005;20(7):1867–1875
  65. Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obesity Research. 2002;10(6):551–554
  66. Bellver J, Rossal LP, Bosch E, et al. Obesity and the risk of spontaneous abortion after oocyte donation. Fertility and Sterility. 2003;79(5):1136–1140
  67. Styne-Gross A, Elkind-Hirsch K, Scott RT. Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation. Fertility and Sterility. 2005;83(6):1629–1634
  68. Wang Y, Monteiro C, Popkin BM. Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. The American Journal of Clinical Nutrition. 2002;75(6):971–977
  69. Remer T, Manz F. Role of nutritional status in the regulation of adrenarche. The Journal of Clinical Endocrinology and Metabolism. 1999;84(11):3936–3944
  70. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche—normal variant or forerunner of adult disease?. Endocrine Reviews. 2000;21(6):671–696
  71. Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. The Journal of Clinical Endocrinology and Metabolism. 2003;88(10):4682–4688
  72. Lake JK, Power C, Cole TJ. Women's reproductive health: the role of body mass index in early and adult life. International Journal of Obesity and Related Metabolic Disorders. 1997;21(6):432–438
  73. Taponen S, Martikainen H, Jarvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. The Journal of Clinical Endocrinology and Metabolism. 2003;88(1):141–147
  74. Anon . Finally: best practices available for obesity. Healthcare Benchmarks. 1998;5(9):141–144
  75. Wadden TA, Foster GD. Behavioral treatment of obesity. Medicine Clinics of North America. 2000;84(2):441–461[vii]
  76. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. The New England Journal of Medicine. 2001;345(11):790–797
  77. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine. 2001;344(18):1343–1350
  78. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002;346(6):393–403
  79. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. The New England Journal of Medicine. 2005;353(20):2111–2120
  80. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism. 1995;44(5):611–616
  81. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2003;88(2):812–819
  82. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2000;85(8):2767–2774
  83. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. The Journal of Clinical Endocrinology and Metabolism. 1999;84(4):1470–1474
  84. Pasquali R, Casimirri F, Colella P, Melchionda N. Body fat distribution and weight loss in obese women. The American Journal of Clinical Nutrition. 1989;49(1):185–187
  85. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology. 1992;36(1):105–111
  86. Hamilton-Fairley D, Kiddy D, Anyaoku V, et al. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clinical Endocrinology. 1993;39(3):363–367
  87. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clinical Endocrinology. 1989;31(6):757–763
  88. Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Clinical Endocrinology. 1994;61(4):598–604
  89. Pasquali R, Fabbri R, Venturoli S, et al. Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. American Journal of Obstetrics and Gynecology. 1986;154(1):139–144
  90. Jakubowicz DJ, Nestler JE. 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. The Journal of Clinical Endocrinology and Metabolism. 1997;82(2):556–560
  91. Van Dam EW, Roelfsema F, Veldhuis JD, et al. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. American Journal of Physiology. Endocrinology and Metabolism. 2002;282(4):E865–E872
  92. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Human Reproduction (Oxford, England). 1996;11(9):1884–1891
  93. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Human Reproduction (Oxford, England). 1995;10(10):2705–2712
  94. Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction (Oxford, England). 1998;13(6):1502–1505
  95. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human Reproduction (Oxford, England). 2003;18(9):1928–1932
  96. van Dam EW, Roelfsema F, Veldhuis JD, et al. Retention of estradiol negative feedback relationship to LH predicts ovulation in response to caloric restriction and weight loss in obese patients with polycystic ovary syndrome. American Journal of Physiology. Endocrinology and Metabolism. 2004;286(4):E615–E620
  97. Wabitsch M, Hauner H, Heinze E, et al. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. The Journal of Clinical Endocrinology and Metabolism. 1995;80(12):3469–3475
  98. Reinehr T, de Sousa G, Roth CL, Andler W. Androgens before and after weight loss in obese children. The Journal of Clinical Endocrinology and Metabolism. 2005;90(10):5588–5595
  99. Hoeger KM, Kochman L, Guzick DS. Impact on androgen and cardiovascular risk parameters by treatment of overweight adolescents with polycystic ovary syndrome (PCOS): a randomized 24-week pilot study. Fertility and Sterility. 2004;82(supplement 2):S82

PII: S1521-690X(06)00031-5

doi: 10.1016/j.beem.2006.03.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 293-310 , June 2006

Article Tools

* Image Usage & Resolution